Insmed Inc INSM

NAS: INSM | ISIN: US4576693075 17/09/2026

123,98 USD (+1,14%)

(+1,14%) 17/09/2026

Grafiek Insmed Inc

Grafiek Insmed Inc

1 dag1d 1,14%
1 week1w -1,05%
1 maand1m -5,11%
3 maanden3m 25,73%
6 maanden6m -13,90%
1 jaar1j -14,35%
5 jaar5j 376,66%

Insmed Inc in het nieuws

Toon enkel gratis nieuws

16 september 2026 · Insmed Expands Community Impact During Fifth Annual Global Day of Good · Persbericht

4 september 2026 · Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

3 september 2026 · Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 · Persbericht

26 augustus 2026 · Insmed to Present at September 2026 Investor Conferences · Persbericht

24 augustus 2026 · BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease · Persbericht

6 augustus 2026 · Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update · Persbericht

23 juli 2026 · Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026 · Persbericht

16 juli 2026 · Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension · Persbericht

23 juni 2026 · Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory · Persbericht

4 juni 2026 · Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

Profiel Insmed Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.insmed.com

Hoofdzetel: Bridgewater, New Jersey Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe